FDA Approves Edwards’ Pascal Precision for Tricuspid Repair

Edwards has received FDA approval for Pascal Precision in tricuspid valve repair, according to MassDevice. The approval applies in tricuspid regurgitation and adds a clip-based technology to Edwards’ offerings in the tricuspid valve space.

FDA action in tricuspid repair

MassDevice reported that the FDA approved Pascal Precision for tricuspid valve repair. The publication identified the system as a clip-based option for tricuspid regurgitation.

The FDA decision is a regulatory update for professionals following structural heart technologies and tricuspid valve intervention. It puts Pascal Precision among the Edwards products associated with treatment of tricuspid regurgitation, based on MassDevice’s report.

For medical-device sales professionals, the development centers on the product’s FDA approval and its reported role in tricuspid valve repair. Product conversations can remain focused on the distinction MassDevice drew between a clip-based repair system and an implant used for valve replacement.

Pascal Precision alongside Evoque

According to MassDevice, Pascal Precision joins Edwards’ Evoque implant in the company’s tricuspid valve portfolio. MassDevice described Evoque as an implant for replacing the valve, while Pascal Precision is a clip-based system for repair.

The report places repair and replacement approaches alongside one another in Edwards’ tricuspid valve offerings. That distinction is the central portfolio context supplied by MassDevice following the FDA action.

• Pascal Precision: clip-based tricuspid valve repair
• Evoque: tricuspid valve replacement implant

What the announcement establishes

MassDevice’s report establishes that Edwards has FDA approval for Pascal Precision in tricuspid valve repair for tricuspid regurgitation. It also identifies the product’s relationship to Evoque within the company’s tricuspid valve offerings.

For teams tracking FDA activity in cardiovascular devices, the announcement is a focused update involving an approved repair technology and a reported replacement implant in the same valve area. The available report does not provide further details on the FDA action beyond the approval and the repair-and-replacement positioning of the two Edwards products.